CellTran Ltd.

https://www.celltran.com

CellTran is a UK biotechnology company specialising in developing cell therapies to heal wounds. Incorporated in 2000, CellTran has raised over £4 million in venture finance. This has enabled CellTran to trial and launch myskin™ in the UK. The positive response from clinicians and patients alike is highlighted by the fact that myskin™ has been supplied to burns, plastics and vascular specialties as well as to the initial target market of foot ulcer wound care clinicians. CellTran benefits from a distribution agreement with Vernon Carus, and is currently negotiating licensing deals for myskin™ in territories outside the UK, as well as exploring new routes to market in the UK. With growing revenues and license income, supported by a strong development pipeline, CellTran continues to build value for its majority shareholders; BioFusion plc, White Rose Technology Limited, Yorkshire Fund Managers, Partnerships UK and the Wellcome Trust. *

	Start	2002-01-15 existent
	Group	Abbott (Group)
	Industry	tissues

	Region	United Kingdom (town unspecified)
	Country	United Kingdom (GB)
	Street	217 Portobello, The Innovation Centre
	City	S1 4DP Sheffield
	Tel	+44-114-2220980
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Abbott (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)